非二尖瓣心脏手术后退行性二尖瓣反流:MitraClip与外科重建对比
该回顾性分析纳入131例既往心脏手术后又因严重退行性二尖瓣脱垂接受干预的患者,其中75例(57.3%)行外科修复,56例(42.7%)行MitraClip置入。MitraClip组患者更老且STS风险评分更高,30天死亡率两组相当,但MitraClip组出院及1年随访时中重度复发MR显著更高,1年免于二尖瓣再干预率外科组更高。结论认为再次传统外科手术安全耐久,MitraClip仅适用于精选患者。
要点
- 既往心脏手术后严重退行性MVP,再次外科修复安全且耐久。
- MitraClip组残余MR风险显著高于外科组,应仅用于精选患者。
- 建议心脏团队仔细评估患者以选择干预方式。
核心结论
- 在既往心脏干预且严重退行性MVP患者中,再次传统外科手术安全且耐久,而MitraClip修复有效但残余MR风险更高,应仅考虑用于精选患者。
研究设计与样本
- 回顾性分析2012年1月至2016年5月131例既往心脏手术后因退行性MVP接受干预的患者,75例(57.3%)行外科修复,56例(42.7%)行MitraClip置入。
主要发现
- MitraClip组年龄更大(75.7 ± 8.6岁 vs 68.6 ± 13.1岁;p < 0.001),STS风险评分更高(5.8 ± 2.4 vs 2.7 ± 2.3;p < 0.001)。
- 中位住院时间外科组7天(IQR 5-11),MitraClip组2天(IQR 2-4)(p < 0.001),但30天死亡率两组相当(2.7% vs 3.6%;p = 0.77)。
- 复发中重度MR在MitraClip组显著更高:出院时43.1% vs 5.4%(p < 0.001),1年随访时66.7% vs 33.3%(p = 0.02)。
- 1年免于二尖瓣再干预率外科组显著更高(100.0% vs 87.5%;p = 0.006)。
临床怎么用
- 对于既往心脏手术后严重退行性MVP患者,再次传统外科修复可作为安全耐久的选择。
- MitraClip应仅用于经心脏团队评估的精选患者,并告知残余MR风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical mitral valve repair is the conventional treatment for severe degenerative mitral regurgitation (MR). MitraClip therapy has emerged as a viable option in high-risk surgical patients. We sought to compare conventional surgery to MitraClip therapy in patients with severe degenerative mitral valve prolapse (MVP) and previous cardiac interventions. METHODS: From January 2012 to May 2016, 131 patients with previous cardiac surgery and subsequent intervention for degenerative MVP were included in this analysis: 75 (57.3%) underwent surgical repair and 56 (42.7%) underwent MitraClip placement. Follow-up was available in all early survivors at median of 11 (interquartile range, 0 to 32) months for surgery and 11 (interquartile range, 3 to 21) months for MitraClip patients. RESULTS: MitraClip patients were older (75.7 ± 8.6 years of age versus 68.6 ± 13.1 of age; p < 0.001), and had higher Society of Thoracic Surgeons risk scores (5.8 ± 2.4 versus 2.7 ± 2.3; p < 0.001). Median length-of-stay was 7 (interquartile range, 5 to 11) days for surgery and 2 (interquartile range, 2 to 4) days for MitraClip patients (p < 0.001), but 30-day mortality was comparable between the 2 groups (2.7% versus 3.6%; p = 0.77). Recurrent MR (moderate or severe) was significantly higher for MitraClip patients, both at discharge (43.1% versus 5.4%; p < 0.001) and at 1-year follow-up (66.7% versus 33.3%; p = 0.02). At 1 year postintervention, freedom from mitral reintervention was significantly higher for surgical patients (100.0% versus 87.5%; p = 0.006). CONCLUSIONS: In patients with previous cardiac interventions and severe degenerative MVP, a repeat conventional surgery is safe and durable. Percutaneous MitraClip repair is effective but associated with higher risk of residual MR, and should only be considered in selected patients. Careful patient selection using a heart team approach is recommended.
引用
- Anwer LA, Dearani JA, Daly RC, et al. Degenerative Mitral Regurgitation After Nonmitral Cardiac Surgery: MitraClip Versus Surgical Reconstruction. Ann Thorac Surg. 2018. PMID: 30395854. doi:10.1016/j.athoracsur.2018.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。